Kairos Pharma, Ltd.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kairos Pharma, Ltd. (NASDAQ: KAPA) is a clinical-stage biopharmaceutical company developing innovative cancer therapies targeting the tumor microenvironment and novel targets. The company offers a pipeline of proprietary drug candidates, including its lead product KROS101, a first-in-class oral small molecule inhibitor of CD206 expressed on tumor-associated macrophages that reprograms immunosuppressive tumor macrophages into tumor-killing cells; KROS102, an anti-cancer immunotherapy agent targeting ENPP1 to enhance the efficacy of immune checkpoint inhibitors; and KROS201, a novel antibody-drug conjugate targeting CD25-positive regulatory T cells in tumors. Kairos Pharma manufactures and advances these oncology therapeutics through clinical development stages, with operations focused on the United States and South Korea. Founded in 2018 and headquartered in San Diego, California, the company maintains research and development facilities in South Korea through its subsidiary Kairos Pharma Co., Ltd. In recent developments, Kairos Pharma completed a business combination with Cartesian Therapeutics in October 2024, resulting in its Nasdaq listing under the KAPA ticker; initiated patient dosing in the Phase 1 clinical trial of KROS101 in November 2024; announced positive preclinical data for KROS102 in combination with PD-1 inhibitors; and secured strategic collaborations with leading Korean biopharma entities for pipeline advancement.
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy
Kapa Gold Announces the Results of Its 2026 Annual General Meeting
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law Firm
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
Kairos Pharma (NYSEAMERICAN:KAPA) Trading Down 2.2% – What’s Next?
Kairos Pharma Provides Shareholder Update
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year